CORRECTION

Errors in the Results and Supplement: In the Original Investigation titled “Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence,” published in the January 2021 issue, there were errors in the Results and eTable 9 in the Supplement. In the ELISA Validation section in the Results, the last sentence should be the following: “The A2M [alpha-2-macroglobulin] mean in CHR-T [participants at clinical high risk who transitioned to first-episode psychosis] was 117.3 μg/mL vs 150.7 μg/mL in CHR-NT [participants at clinical high risk who did not transition to psychosis] (FDR [false discovery rate]-corrected P = .02).” In the Supplement, the first value in the CHR-NT mean (SD) column should be 150.7 (711.1). This article was corrected online.


Error in Results: In the Original Investigation titled “Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial,” published in the September 2021 issue, there was an error in the Results section. The number of patients in the zuranolone and placebo groups who had new antidepressant medication treatment initiated by investigators were switched and should be 6 and 4, respectively. This article has been corrected online.


Change to Open Access Status: The Brief Report titled “Contrasting Case-Control and Normative Reference Approaches to Capture Clinically Relevant Structural Brain Abnormalities in Patients With First-Episode Psychosis Who Are Antipsychotic Naive,” published online September 28, 2022, was changed to open access status under the CC-BY license. This article was corrected online.